Alexandros Rampotas, Matthew R Wilson, Oliver Lomas, Nicholas Denny, Heather Leary, Graeme Ferguson, Pamela McKay, Tim Ebsworth, Jonathan Miller, Nimish Shah, Nicolas Martinez-Calle, Mark Bishton, Angharad Everden, David Tucker, Ezzat El-Hassad, Brian Hennessy, Dearbhla Doherty, Steve Prideaux, Rehman Faryal, Amjad Hayat, Clodagh Keohane, Helen Marr, Adam Gibb, Rachael Pocock, Jonathan Lambert, Rachel Lacey, Nagah Elmusharaf, Ruth Clifford, Toby A Eyre
Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line 'attenuated' or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenuated immunochemotherapy in 95 patients with MCL across 19 centres in the UK and Ireland considered unfit for full-dose rituximab-bendamustine or rituximab-cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP). Regimens examined were rituximab-cyclophosphamide, vincristine, prednisolone (R-CVP) (n = 19), dose-attenuated R-CHOP (n = 22), dose attenuated rituximab-bendamustine (n = 24) and rituximab-chlorambucil (n = 30)...
July 2021: British Journal of Haematology